<p>Renalytix AI Plc (RENXF) 发布了其第四季度财报。以下是 Renalytix AI Plc 向投资者提供的信息概述。</p>
<h3>TipRanks 网络星期一促销</h3>
<ul>
<li>享受 TipRanks Premium 60% 的折扣，获取数据驱动的洞察和您需要的研究工具，以自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据，现在也享受 60% 的折扣。</li>
</ul>
<p>Renalytix AI Plc 是一家在肾脏健康生物预后领域的先锋公司，专注于通过其 FDA 批准的 KidneyIntelX 平台进行早期慢性肾病风险评估。该公司在 2025 财年报告了显著增长，总收入增长了 30%，商业检测量上升了 37%，这得益于战略合作伙伴关系和 Medicare 对其 KidneyIntelX.dkd 测试的报销。关键财务亮点包括行政费用大幅减少超过 40%，基础 EBITDA 亏损减少 54%，同时成功筹集资金总额达到 1850 万英镑。Renalytix 还通过与 MVP Health Care 和 Tempus AI 等新合作伙伴关系扩大了市场影响力，增强了其分销网络并支持其增长战略。展望未来，Renalytix 专注于进一步将其 KidneyIntelX 技术整合到电子病历中，扩大其保险支付方覆盖范围，并追求国际市场机会，以继续在肾病管理领域的增长和创新轨迹。</p>

RNLXY

RNLXD

<p>Renalytix AI Plc 在其 2025 财年报告了强劲的增长，收入增长 30%，商业测试量上升 37%。公司将行政费用减少了超过 40%，EBITDA 亏损减少了 54%。成功的资本筹集总额达到 1850 万英镑。战略合作伙伴关系和医疗保险报销促进了增长。未来计划包括扩展 KidneyIntelX 技术整合、保险覆盖和国际市场机会</p>

<p>Renalytix AI Plc ( (RENXF) ) has released its Q4 earnings. Here is a breakdown of the information Renalytix AI Plc presented to its investors.</p>
<div class="lb-trans"><p>Renalytix AI Plc (RENXF) 发布了其第四季度财报。以下是 Renalytix AI Plc 向投资者提供的信息概述。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 网络星期一促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 60% 的折扣，获取数据驱动的洞察和您需要的研究工具，以自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据，现在也享受 60% 的折扣。</li>
</ul>
</div><p>Renalytix AI Plc is a pioneering company in the field of bioprognosis for kidney health, focusing on early-stage chronic kidney disease risk assessment through its FDA-approved KidneyIntelX platform. The company has reported significant growth in its 2025 financial year, with a 30% increase in total revenues and a 37% rise in commercial testing volumes, driven by strategic partnerships and Medicare reimbursement for its KidneyIntelX.dkd test. Key financial highlights include a substantial reduction in administrative expenses by over 40% and a 54% decrease in underlying EBITDA loss, alongside successful capital raises totaling £18.5 million. Renalytix has also expanded its market presence with new partnerships, such as those with MVP Health Care and Tempus AI, enhancing its distribution network and supporting its growth strategy. Looking ahead, Renalytix is focused on further integrating its KidneyIntelX technology into electronic medical records, expanding its insurance payor coverage, and pursuing international market opportunities to continue its trajectory of growth and innovation in kidney disease management.</p>
<div class="lb-trans"><p>Renalytix AI Plc 是一家在肾脏健康生物预后领域的先锋公司，专注于通过其 FDA 批准的 KidneyIntelX 平台进行早期慢性肾病风险评估。该公司在 2025 财年报告了显著增长，总收入增长了 30%，商业检测量上升了 37%，这得益于战略合作伙伴关系和 Medicare 对其 KidneyIntelX.dkd 测试的报销。关键财务亮点包括行政费用大幅减少超过 40%，基础 EBITDA 亏损减少 54%，同时成功筹集资金总额达到 1850 万英镑。Renalytix 还通过与 MVP Health Care 和 Tempus AI 等新合作伙伴关系扩大了市场影响力，增强了其分销网络并支持其增长战略。展望未来，Renalytix 专注于进一步将其 KidneyIntelX 技术整合到电子病历中，扩大其保险支付方覆盖范围，并追求国际市场机会，以继续在肾病管理领域的增长和创新轨迹。</p>
</div>

Renalytix AI 报告显示强劲增长和战略扩张